600 ovarian cancer patients help unlock secrets of drug resistance
NCT ID NCT03954171
First seen Nov 18, 2025 · Last updated Jun 13, 2026 · Updated 25 times
Summary
This study follows 600 people with epithelial ovarian cancer to find out why some tumors stop responding to platinum-based chemotherapy. Participants receive standard treatment and provide blood, tumor, and fluid samples over 5 years. No new drugs are tested; the goal is to collect data and samples for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Universitaire du Cancer de Toulouse - Oncopole
RECRUITINGToulouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.